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Abstract
Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint
blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1
(PD-1) have demonstrated acceptable toxicity, promising clinical responses, durable disease control, and improved
survival in some patients with advanced melanoma, non-small cell lung cancer (NSCLC), and other tumor types.
About 20 % of advanced NSCLC patients and 30 % of advanced melanoma patients experience tumor responses
from checkpoint blockade monotherapy, with better clinical responses seen with the combination of anti-PD-1 and
anti-CTLA-4 antibodies. Given the power of these new therapies, it is important to understand the complex and
dynamic nature of host immune responses and the regulation of additional molecules in the tumor microenvironment
and normal organs in response to the checkpoint blockade therapies. In this era of precision oncology, there remains
a largely unmet need to identify the patients who are most likely to benefit from immunotherapy, to optimize
the monitoring assays for tumor-specific immune responses, to develop strategies to improve clinical efficacy, and
to identify biomarkers so that immune-related adverse events can be avoided. At this time, PD-L1 immunohistochemistry
(IHC) staining using 22C3 antibody is the only FDA-approved companion diagnostic for patients with NSCLC-treated
pembrolizumab, but more are expected to come to market. We here summarize the current knowledge, clinical efficacy,
potential immune biomarkers, and associated assays for immune checkpoint blockade therapies in advanced
solid tumors.
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Background
Since 2011, when the US Food and Drug Administration
(FDA) approved ipilimumab for advanced melanoma,
there has been an explosion of research interest and
drug development for harnessing the immune system to
fight against cancer. A general search for “immune ther-
apy and cancer” in the clinicaltrials.gov database from
2000 to 2010 shows 640 hits, while the same search on
March 20, 2015 shows 7815 hits and December 23, 2015
shows 8941 hits. Active research in tumor immunology
includes studies on adoptive T cell therapy and cancer
vaccine, as well as clinical investigations into immune
checkpoint blockade in monotherapy or combination
therapies. First generation programed cell-death protein
1 (PD-1) blockade antibodies pembrolizumab and nivo-
lumab obtained US FDA approval for advanced melan-
oma in 2014 and as second line therapy for non-small
cell lung cancer (NSCLC) in 2015. We have seen a surge
in the availability of immune checkpoint inhibitors for
multiple cancer indications. Forecasts for 2013–2020
project that the market for immunotherapy will increase
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from approximately $1 billion (US dollars) in 2013 to in
excess of $7 billion in 2020 (corresponding to 33 % an-
nual growth), across the seven major markets (USA,
France, Germany, Italy, Spain, UK, and Japan) [1].
Unlike chemotherapy and molecularly targeted ther-
apy, the checkpoint blockade immunotherapies result in
durable clinical responses through the induction, activa-
tion, and expansion of tumor-specific cytotoxic T cells.
Immune checkpoints play an essential role in maintain-
ing self-tolerance and regulating the amplitude and dur-
ation of T cell responses. Two cytotoxic T cell immune
checkpoint receptors (cytotoxic T-lymphocyte antigen 4
(CTLA-4) and PD-1) deliver inhibitory signals when
bound to their respective ligands CD80/86 and pro-
gramed cell-death ligand 1 (PD-L1)/2. Immunotherapies
with checkpoint blockade antibodies that block CTLA-4
and PD-1 (or its ligand PD-L1) can restore and augment
cytotoxic T cell responses against chemotherapy-refractory
tumors, leading to durable responses and prolonged overall
survival with tolerable toxicity. In the lymphatic tissues,
anti-CTLA-4 antibody induces non-tumor-specific im-
mune activation that is largely de novo induction of
new responses. In tumor microenvironment, anti-PD-1/
PD-L1 antibody targets tumor-induced immune defects
and repairing ongoing tumor immunity. In addition to
these anti-CTLA-4 and anti-PD-1/PD-L1 antibodies,
drugs targeting other immune checkpoints and/or co-
stimulatory ligand-receptor inhibitors, such as lymphocyte
activation gene 3 protein (LAG3) and T cell immuno-
globulin and mucin-domain containing protein 3 (TIM-3),
are currently being explored in many tumor types and will
be discussed further in the “Principles of cancer immuno-
therapy” section.
Given the distinct and novel mechanisms of action of
immunotherapy on effector immune cells, rather than
tumor cells, there are emerging tumor response patterns
that are not accurately assessed by Response Evaluation
Criteria in Solid Tumors (RECIST). In 2009, a guideline
for immune-related response criteria (irRC) was pro-
posed for patients with advanced melanoma receiving
ipilimumab [2]. This guideline has been used to evaluate
the tumor response for ongoing immune checkpoint
blockade therapies [3]. When assessed appropriately,
approximately 20 % of advanced NSCLC patients and
30–40 % of advanced melanoma patients have objective
tumor responses to PD-1 blockade monotherapy. The
combination of anti-PD-1 and anti-CTLA-4 antibodies
increased the clinical response in advanced melanoma
patients with a recent FDA approval [4]. In an attempt
to increase the therapeutic, in checkpoint inhibitors, a
companion diagnostic of PD-L1 immunohistochemistry
(IHC) had been approved by the US FDA for selecting
NSCLC patients treated with pembrolizumab. Interest-
ingly, overall tumor responses, progression-free survival
(PFS) and overall survival (OS) were not consistently as-
sociated with PD-L1 expression in the patients receiving
immune checkpoint inhibitors [5]. In this age of person-
alized medicine, finding and validating better immune
biomarkers will enable us to select patients for cancer
immunotherapies. It will also lead to a better under-
standing of the unique mechanisms of tumor response
and resistance, to allow for the development of strategies
to improve clinical efficacy, and to lead to better evalu-
ation of response and monitoring assays for host im-
mune function. Validating potential immune biomarkers
will enable us to better select patients for cancer im-
munotherapies and to avoid immune-related adverse ef-
fects (irAEs). Many excellent review articles on cancer
biomarkers and immune checkpoint inhibitors have been
recently published [6–12]. In this review, we will focus on
the current knowledge, clinical efficacy, available monitor-
ing assays, and emerging novel technologies for identifying
translational biomarkers for immune checkpoint blockade
immunotherapies in advanced solid tumors.
Principles of cancer immunotherapy
Clinically apparent cancer can be thought of as a host’s
inability to eliminate transformed cells. Cancer im-
munotherapy refers to a diverse range of therapeutic
approaches that harness the immune system to induce
or restore the capacity of cytotoxic T cells, and other
immune effector cells, and to recognize and eliminate
cancer [13, 14]. The field of cancer immunotherapy is
undergoing a renaissance due to a greater understand-
ing of the immune system and immunosurveillance. The
immune system protects the host against tumor develop-
ment but also promotes tumor growth by selecting for
tumors of lower immunogenicity. This dual effect of the
immune system on developing tumors creates a dynamic
process termed cancer immunoediting, which is com-
prised of three phases: elimination, equilibrium, and es-
cape [15]. Cancer cells are immunogenic through the
generation of tumor-specific mutant antigens (TSMA,
neoantigens) from somatic gene structural and/or epi-
genetic alterations [16]. During the elimination phase,
immune effector cells (mainly T and natural killer (NK)
lymphocytes) are activated by the inflammatory cyto-
kines released by the growing tumor cells, macro-
phages, and stromal cells surrounding the tumor cells.
The recruited tumor-infiltrating NK cells and macro-
phages produce interleukin 2 (IL-2), interleukin 12 (IL-
12), and interferon gamma (IFNγ), which kill tumor
cells by cytotoxic mechanisms such as perforin, tumor
necrosis factors (TNF)-related apoptosis-inducing li-
gands (TRAILs), and reactive oxygen species. Due to
heterogeneity, tumor cells with a less immunogenic pheno-
type are able to escape this elimination phase (i.e., immu-
nosurveillance) and expand during the equilibrium phase.
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The equilibrium phase may occur over a period of many
years when, under Darwinian selection, new tumor cell
variants emerge with mutations that further increase over-
all resistance to immune attack. During the escape phase,
tumor cell variants breach the host’s immune defenses con-
ferring further resistance to immune detection [17].
Major mechanisms for escape include defective anti-
gen presentation, tumor-induced inhibitory checkpoint
pathways against effector T cell activity, infiltrating
immunosuppressive immune cells including regulatory T
cells (Treg) and myeloid-derived suppressor cells (MDSCs),
and secretion of immunosuppressive cytokines (transform-
ing growth factor beta (TGF-β), IL-6, vascular endothelial
growth factor (VEGF)) [7, 18, 19]. Full activation of T and
NK lymphocytes requires the coordinated participation of
several surface receptors that meet their cognate li-
gands through structured transient cell-to-cell interac-
tions known as immune synapses. Current PD-1/PD-L1
blockade therapies aim to boost the patient’s effector T
cells to specifically recognize and kill cancer cells.
Table 1 summarizes the current list of major immune
checkpoint inhibitors that have obtained FDA approval or
are in the late phases of clinical development.
Immune checkpoints normally maintain self-tolerance,
regulate the amplitude and duration of T cell responses,
and prevent tissue damage. PD-1 and PD-L1 immune
checkpoint blockade can restore the function of exhausted
CD8 T cells in chronic viral infection, augmenting the
existing tumor-specific immunity [20, 21]. Nevertheless,
immune checkpoint inhibitors can override immune self-
tolerance, inducing a unique syndrome of autoimmune
and autoinflammatory side effects (i.e., irAEs) [22]. Many
of these irAEs resemble autoimmune diseases, such as
autoinflammatory rheumatic disease, dermatologic disease,
colitis, hepatitis, and endocrinopathies [23]. Therefore, al-
most all immunotherapy clinical trials have excluded indi-
viduals with preexisting autoimmune diseases, although a
recent study demonstrates that the use of ipilimumab in
cancer patients with autoimmune diseases is safe and ef-
fective [24]. However, a recent study showed the safety
and efficacy of using anti-CTLA-4 antibody in patients
with autoimmune disease [24]. Early detection and effect-
ive management of these irAEs are pivotal for a favorable
clinical outcome. Theoretically, cytotoxic T cells against
tumors and normal organs are different subclones that
may not need to be activated in parallel. Further studies
are warranted to specifically enhance tumor-specific cyto-
toxic T cell response and avoid unnecessary T cell re-
sponse to normal tissues.
Biology and mechanisms of PD-1 and PD-L1
molecules
PD-1 (CD279) is expressed on many cell types including
T cells, B cells, natural killer T cells, activated monocytes,
and dendritic cells (DCs) in humans and mice [25]. In
normal human lymphoid tissues, PD-1 is detected on ger-
minal center-associated T cells [26]. PD-1 binds to the lig-
and PD-L1 (B7-H1, CD274) or PD-L2 (B7-DC, CD272).
PD-L1 is typically expressed on the surface of tumor cells
[27]. PD-L1 is also constitutively expressed on other cell
types such as T and B cells, DCs, macrophages, mesenchy-
mal stem cells, and bone marrow-derived mast cells [28].
Cell surface expression of PD-L1 can be upregulated
on both tumor cells and other cell types after treatment
with type I or type II interferons (IFNs) [29, 30], radiation
[31–33], or chemotherapy [34–38]. Additionally, radio-
therapy may induce direct tumor-cell killing and multiple
immunomodulatory changes that can potentially influence
the effectiveness of immunotherapy [31–33].
Engagement of PD-1 by its ligands, either PD-L1 or PD-
L2, induces a negative control signal resulting in the inhib-
ition of T cell proliferation, cytokine production, and
cytotoxic activity. PD-L1 can provide inhibitory signals
to activated T cells through interactions with the sur-
face receptor PD-1 or CD80 [25, 39]. These signals en-
able PD-L1-expressing tumor cells to evade immune
detection by NK cells or T cells [40–42]. PD-L2 is encoded
by PDCD1LG2, which is essential for T cell proliferation
and IFN production. PD-L2 can stimulate PD-1 receptor
signaling, resulting in “T cell exhaustion,” a temporary in-
hibition of activation and proliferation that can be re-
versed by the removal of PD-1 signal [25].
Upregulation of PD-L1 on different tumor types inhibits
the local antitumor T cell response. Figure 1 illustrates the
expression and complex interaction of key molecules and
co-stimulatory ligand receptors between tumor and im-
mune cells in tumor microenvironment (TME), and the
two potential mechanisms proposed to understand the
biology and function of PD-L1 on tumor cells [43]. While
constitutive oncogenic signals (such as protein kinase B
(AKT), epidermal growth factor receptor (EGFR), KRAS
pathways) upregulate PD-L1 expression on tumors as in-
nate (tumor cell intrinsic) resistance (Fig. 1, left) [44–48],
inflammatory signals generate cytokine-induced PD-L1
expression on either tumor cells or immune cells (mye-
loid suppressor cells, dendritic cell, macrophage, and lym-
phocytes) in the tumor microenvironment as adaptive
resistance (Fig. 1, right) [49, 50]. Preclinical studies have
demonstrated that blocking the PD-L1/PD-1 interaction in-
creases the numbers of effector T cells, augments cytolytic
activity of tumor-specific T cells, enhances the production
of pro-inflammatory cytokines, brings effector T cells to the
tumor sites, reduces numbers and suppression of Tregs at
the tumor site, and downregulates the production of sup-
pressive cytokines IL-10 [51–54]. Tumor-infiltrating T cells
may also be functionally inert, due in part to the expression
of PD-1 along with other inhibitory receptors [27, 55]. The
hallmarks of the PD-1/PD-L1 blockage effect include
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Table 1 Summary of clinical indication and ongoing evaluation of immune checkpoint inhibitors in major cancer types








Metastatic melanoma (US FDA approved on March 25, 2011); metastatic
NSCLC (phase I has been completed; NCT01165216; Japan; phase II
reported, NCT00527735, USA; phase III ongoing, NCT01285609; USA;








Metastatic melanoma (phase I has been completed; NCT01103635; USA;
phase II has been completed, NCT00471887, USA); advanced hepatocellular
carcinoma (phase II has been completed; NCT01008358; Spain); Metastatic
NSCLC (phase Ib has been reported, NCT02000947, USA; phase II has been










Metastatic melanoma (Japan approval on July 4, 2014; US FDA accelerated
approval on December 22, 2014; US FDA approval of nivolumab in
combination with ipilimumab for BRAF V600 wild-type tumor on
September 30, 2015); Squamous NSCLC (US FDA approval on March 4,
2015; European Commission on July 20, 2015); expands to non-squamous
NSCLC (US FDA approval on October 9, 2015); advanced (metastatic) renal
cell carcinoma (US FDA approval on November 23, 2015); classical Hodgkin
lymphoma that has relapsed or progressed after autologous hematopoietic
stem cell transplantation and post-transplantation brentuximab vedotin





Merck & Co. Metastatic melanoma (USA accelerated approval on September 4, 2014 for
patients with disease progression after ipilimumab and, if BRAF V600
mutation positive, a BRAF inhibitor; US FDA expanded to initial treatment
on December 18, 2015); metastatic NSCLC whose tumors express PD-L1 as
determined by an FDA-approved test and who have disease progression






CureTech Ltd Diffuse large-B cell lymphoma (phase II has been completed; NCT00532259;










Cancer (preclinical phase, Aurigene granted Pierre Fabre worldwide rights










Human IgG1 Roche &
Genentech
Metastatic bladder cancer (phase III, US FDA granted breakthrough therapy
designation on May 31, 2014; priority review on March 14, 2016; accelerated
approval on May 18, 2016); metastatic NSCLC (phase III, US FDA grants





AstraZeneca Glioblastoma (phase II is currently recruiting participants; NCT02336165;
USA); metastatic squamous cell carcinoma of the head and neck (phase II is
currently recruiting participants; NCT02207530; USA); advanced or
metastatic NSCLC (phase III is currently recruiting participants;
NCT02352948; Global study); advanced colorectal cancer (phase II is
currently recruiting participants; NCT02227667; USA); metastatic NSCLC
(first line phase III MYSTIC is current recruiting participants; NCT02453282;
USA; first line phase III ARCTIC is current recruiting participants;
NCT02352948; Global); metastatic bladder cancer (US FDA granted
breakthrough therapy designation for PD-L1-positive tumors in patients









Advanced solid tumors (phase I with consecutive parallel group expansion;
currently recruiting participants in multiple tumor types and settings;
NCT01772004; USA); metastatic NSCLC (phase III is currently recruiting
participants after failure of a platinum-based doublet; NCT02395172; and
first line versus platinum doublet; NCT02576574; USA)
PD-L2 AMP-224 PD-L2-IgG2a
fusion protein
Amplimmune Advanced cancer (phase II has been completed; NCT01352884; USA)
Last assessed information at ClinicalTrial.gov on December 28, 2015; updated FDA approvals on May 18, 2016. Italicized data highlights major cancer types in
clinical evaluation
Abbreviations: CTLA-4 cytotoxic T-lymphocyte-associated protein 4, NSCLC non-small-cell lung cancer, PD1 programed cell-death protein 1, PDL1 programed
cell-death ligand 1
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immune modulation at tumor site, direct targeting of
tumor-induced immune defects, and repairing ongoing
tumor immunity. PD-1 deletion in mice can lead to auto-
immunity, most notably when bred onto backgrounds of
autoimmune-susceptible mouse strains [56, 57]. In multiple
syngeneic mouse tumor models, blockade of PD-1 or its li-
gands promotes antitumor activity [58, 59]; anti-PD-1 activ-
ity in vivo can be enhanced by combination with antibodies
to other T cell-negative regulators, such as CTLA-4 and
LAG-3 [60–62]. A recent study suggests that PD-L1 is an
independent prognostic marker in melanoma, defining a
tumor subset with distinct genetic and morphophenotypic
features [63].
Clinical efficacy of PD-1/PD-L1 blockade therapies
and PD-L1 expression
Nivolumab and pembrolizumab are the first generation
PD-1 immune checkpoint blockade antibodies. Nivolu-
mab inhibits the interaction between PD-1 and its li-
gands, PD-L1, and PD-L2 with similar IC50 values (2.52
and 2.59 nmol/L, respectively). Nivolumab enhances T
cell reactivity in the presence of a T cell receptor stimu-
lus at the low concentration (~1.5 ng/mL) without non-
specific lymphocyte activation. Nivolumab also enhances
the production of inflammatory cytokines in assays such
as the human T cell/DC-mixed lymphocyte reaction
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Fig. 1 Schema interaction between tumor and immune cells. Full activation of T-lymphocytes requires the coordinated participation of several
surface receptors on effector T cells and antigen-presenting cells (APCs) or tumor cells. The main route of T cell stimulation is driven by antigens
recognized in the form of short polypeptides associated with MHC antigen-presenting molecules. However, the functional outcome of T cell
stimulation towards clonal expansion and effector function acquisition is contingent on the contact of additional surface receptor-ligand pairs
and on the actions of cytokines in the tumor microenvironment. While some of those interactions are inhibitory (in red), others are activating and
are collectively termed co-stimulatory (in green) receptors. Communication between T cells and APCs is bidirectional. In some cases, this occurs
when ligands themselves signal to the APC. In other cases, activated T cells upregulate ligands, such as CD40L, that engage cognate receptors on
APCs. Tumor cells can upregulate PD-L1 expression via either the constitutionally activated oncogenic signaling (left, innate/intrinsic immune
resistance) or the immune modulator-induced signaling pathways (right, adaptive immune resistance). Abbreviations: APC antigen-presenting
cells, DC dendritic cell, IL-2R IL-2 receptor, MDSCs myeloid-derived suppressor cells, Teff effector T cell, Treg regulatory T cells, IDO indoleamin
2,3-dioxygenase, TIM-3 T cell immunoglobulin domain and mucin domain, LAG lymphocyte-activation gene, BTLA B- and T-lymphocyte attenuator,
HVEM herpes virus entry mediator, TIGIT T cell immunoreceptor with Ig and ITIM domains, GITR glucocorticoid-induced tumor necrosis factor
receptor, ICOS inducible costimulators, CEACAM carcinoembryonic antigen-related cell adhesion molecule, TSMA tumor-specific mutant anti-
gens, JNK, c-Jun N-terminal kinase, MEK/ERK, mitogen/extracellular signal regulated kinase, PI3K, phosphatidylinositol 3-kinase, STAT, signal trans-
ducer and activator of transcription, NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells
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and cytomegalovirus (CMV) recall response assays. In
addition, nivolumab increases antigen-specific CD8+ T
cell responses in patients with melanoma [64]. Nivolumab
completely restored CD4+ T-responder cell proliferation
and partially restored IFNγ production. Nivolumab also
overcomes Treg suppression of CD8+ T cells by increasing
resistance to Treg suppression and also by directly limiting
suppressive capacity of Treg [65]. This was demonstrated
in monkeys when increased numbers of CD8+ T-effector
memory cells were detected in CMV-positive peripheral
blood after repeated treatment at the highest dose of nivo-
lumab for 3 months. Similarly, marked accumulation of
CD8+ effector memory T cells in lymphoid organs and tis-
sues of PD-1-deficient mice has been described [66].
Both nivolumab and pembrolizumab have shown signifi-
cant survival benefit in some patients with advanced melan-
oma, NSCLC, and renal cell carcinomas in early clinical
trials (Table 1). These agents were generally well tolerated,
even in elderly patients with prolonged dosing. Lower
tumor response rates have been observed in never smokers
and patients with EGFR mutations or ALK rearrangements
when compared to heavy smokers. Table 2 summarizes this
clinical efficacy data from four of the most studied PD-1
and PD-L1 inhibitors at various stages of clinical develop-
ment. As only subsets of patients are benefiting from the
PD-1/PD-L1 immune checkpoint blockade therapies, it is
important to try to select for this population so that pa-
tients less likely to improve with therapy can be spared
toxicities. An additional challenge is that response criteria
used for standard therapy may not be applicable for im-
munotherapy. Unlike standard therapeutics in which
tumor response is measured by a variety of radiographic
and laboratory tests every 6–8 weeks, delayed tumor re-
sponses due to the time required for activation and func-
tion of effector T cells are frequently observed in cancer
patients treated with immune checkpoint blockade ther-
apies. In some patients, tumor regression persisted after
discontinuation of PD-1 blockade therapy [67]. Evaluating
responses appropriately and identifying patients who are
most likely to respond are important aspects of immuno-
therapy that continue to be developed.
Biomarkers for PD-1/PD-L1 blockade therapies
Translational biomarker research is critical for the future of
drug development for clinical immune checkpoint blockade
therapy. Only one PD-L1 IHC has been approved as a com-
panion diagnostic by the US FDA for patients with ad-
vanced NSCLC for pembrolizumab [68]. The challenges in
developing immuno-oncology biomarkers for clinical use
have been recognized by regulatory agencies and profes-
sional societies such as the Society for Immunotherapy of
Cancer (SITC) [69]. Over the past several years, the SITC
Immune Biomarkers Task force has provided the roadmap
and regular updates on immune biomarker development
[70–72]. Immunological changes in peripheral blood and
tumor could potentially reflect tumor response in patients
and serve as immune biomarkers. The immune monitoring
assays had been developed to evaluate these potential bio-
markers before and after immune checkpoint blockade
therapies and investigate their correlation with clinical out-
come (Fig. 2). These biomarkers could be classified into
two groups: tumor-derived immune biomarkers and im-
mune cell-derived biomarkers as discussed in the following
sections. Table 3 summarizes currently available quantita-
tive biomarker assays for immune checkpoint inhibitors.
Current immune monitoring assays
IHC staining
PD-L1 is the best studied immuno-oncology biomarker to
date. Currently, PD-L1 IHC using 22C3 antibody is the only
FDA-approved companion diagnostic for selecting NSCLC
patients for pembrolizumab [68]. Table 4 summarizes the
IHC assays used for PD-L1 expression using baseline arch-
ival tumor specimens in these clinical studies [73]. There
are many variables in these IHC assays. First, the time be-
tween sample collection and treatment with a PD-1 or PD-
L1 inhibitor is not controlled. Second, tumor cells, immune
cells, as well as stroma cells can express PD-L1 with consid-
erably heterogeneity within the tumor microenvironment.
Third, PD-L1 expression is induced by IFNγ during disease
progression and treatment. Fourth, different PD-L1 anti-
bodies were used for different immune checkpoint block-
ade clinical studies. Currently, there is no validated
antibody for IHC staining for this class of immune check-
point inhibitors—each sponsor uses different antibodies.
Antibodies staining tumor cells or stroma cells may have
different PD-L1 epitopes (Table 4). An additional challenge
is that none of the commercial PD-L1 IHC test has been
validated in terms of clinical outcomes. Head-to-head com-
parisons among three different commercially available PD-
L1 assays (Dako 22C3, Dako 28-8, and Ventana SP263 as
the reference) using 500 formalin-fixed, paraffin-embedded
archival samples of NSCLC tissue obtained from commer-
cial sources found 91 to 95 % correlation, which is compar-
able to typical within assay agreement for IHC across
the dynamic range at multiple cutoffs [74]. A recent
meta-analysis demonstrates that PD-L1 expression is sig-
nificantly associated with clinical response to anti-PD-1/
PD-L1 antibodies in patients with malignant melanoma
(MM) or non-squamous NSCLC. However, a proportion
of PD-L1-negative patients also benefits from anti-PD-1
therapy in MM and squamous-NSCLC. Thus, expression
of PD-L1 in tumor tissues cannot be used as a predictive
biomarker of eligibility for treatment with anti-PD-1/PD-
L1 antibodies. It may represent a correlation marker for
non-squamous NSCLC and melanoma [75].
The presence of tumor-infiltrating lymphocytes (TILs)
at tumor microenvironment has been associated with an
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Nivolumab 3 mg/kg IV
every 2 weeks
20 % 3.5 9.2 Brahmer
J (2015)
[125]
Docetaxel 75 mg/m2 IV
every 3 weeks
9 % 2.8 6
NCT01673867
(CheckMate 057)











Nivolumab 3 mg/kg IV
every 2 weeks
19 % 2.3 12.2 Borghaei
H (2015)
[126]
Docetaxel 75 mg/m2 IV
every 3 weeks
12 % 4.2 9.4
NCT01668784
(CheckMate 025)











Nivolumab 3 mg/kg IV
every 2 weeks
25 % 4.6 25 Motzer
RJ (2015)
[127]
Everolimus 10 mg orally
daily
5 % 4.4 19.6
NCT01721746
(CheckMate 037)














Nivolumab 3 mg/kg IV
every 2 weeks




1000 mg/m2 IV every 3
weeks or carboplatin
AUC = 6 plus paclitaxel
185 mg/m2 IV every
3 weeks
11 % 4.2 NA
NCT01927419
(CheckMate 069)













Nivolumab 1 mg/kg IV
every 3 weeks × 4 doses
plus ipilimumab 3 mg/kg
IV every 3 weeks × 4
doses, then maintenance
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Nivolumab 3 mg/kg IV
every 2 weeks plus
placebo every 3 weeks
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IV every 2 weeks (plus
ipilimumab placebo)




IV every 3 weeks plus
ipilimumab 3 mg/kg
IV every 3 weeks × 4
doses; then maintenance
nivolumab 3 mg/kg
IV every 2 weeks
58 % 11.5
Ipilimumab 3 mg/kg IV

























Unselected Nivolumab at 1, 3, or
10 mg/kg every 2
weeks for up to
96 weeks









Unselected Nivolumab at 1, 3, or
10 mg/kg every 2
weeks for up to
96 weeks









Unselected Nivolumab at 1, 3, or
10 mg/kg every 2
weeks for up to
96 weeks















mg/kg IV every 2 weeks
























Arm A 2 mg/kg
(n = 180)
21 % 5.4 NA Ribas
A (2015)
[135]
Arm B 10 mg/kg
(n = 181)
25 % 5.8
















Table 2 Summary of reported clinical efficacy of PD-1/PD-L1 inhibitors (Continued)
NCT012958297
(KEYNOTE-001)




10 mg/kg IV every
3 weeks or 10 mg/kg
every 2 weeks over a
30-min period
19.4 % 3.7 12 Garon
EB (2015)
[5]
Phase I 655 Melanoma Unselected Pembrolizumab 2 mg/kg
every 3 weeks (Q3W), 10


















after at least 2
ipilimumab doses
Unselected Pembrolizumab 2 mg/kg
IV every 3 week or 10
mg/kg IV every 3 weeks
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IV every 3 weeks
18.5 % 4.0 month 17.3
Docetaxel, 75 mg/m2
every 3 weeks
9.3 % 4.0 month 8.2
NCT01953692
(KEYNOTE-013)
Phase IB 15 Hodgkin lymphoma Unselected Pembrolizumab 10 mg/kg
IV every 2 weeks up to
2 years
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24 % 3.0 9.7


























Table 2 Summary of reported clinical efficacy of PD-1/PD-L1 inhibitors (Continued)




every 3 weeks doses >1
ml/kg
18 % 2.6 NA Herbst
RS (2014)
[145]
NCT01633970 Phase Ib 37 Untreated NSCLC PD-L1-
positive tumor cells
Atezolizumab 15 mg/kg IV






67 % NA NA Stephen
V (2015)
[146]







Arm A: MPDL3280A 20
mg/kg every 3 weeks and
bevacizumab (bev) 15






Arm B: MPDL3280A 14
mg/kg every 2 weeks, bev











given alone on cycle 1
day 1 and concurrently
with 20 mg/kg every
2 weeks thereafter










Durvalumab 10 mg/kg IV
every 2 weeks until
unacceptable toxicity,
disease progression, or
for up to 12 months












(1–25) across 6 cohorts
(0.1–10 mg/kg every
2 weeks; 15 mg/kg
every 3 weeks)















Durvalumab IV every 2
weeks at 10 mg/kg for
12 months





Phase I 26 Advanced solid
tumors
Durvalumab IV every 2
(q2w) or 3 weeks (q3w)
in a 3 + 3 dose escalation
with a 28-day (q2w) or
42-day (q3w) DLT window


















Table 2 Summary of reported clinical efficacy of PD-1/PD-L1 inhibitors (Continued)
NCT02088112 Phase I 10 NSCLC Unselect Durvalumab cohort A
received 3 mg/kg
(starting dose) every
2 weeks plus gefitinib
250 mg QD
NA NA NA Creelan
BC (2015)
[153]


















































improved clinical outcome [76–78], regardless of cancer
treatment. TIL counts are primarily measured by IHC
[79]. Recent development of multicolored immunohisto-
chemistry staining resulted in a multiplex of up to seven
fluorescent dyes effectively interrogated in microscopes
equipped with a multispectral camera [80]. The multispec-
tral fluorescent IHC with a panel including CD3, CD8,
FoxP3, CD163, and PD-L1 was used to quantify the dens-
ity of TIL subpopulation in advanced melanoma patients.
Flow cytometry staining
Flow cytometry traditionally uses fluorochrome-labeled
antibodies to identify cellular protein expression of the
target cells. Flow cytometric analysis of peripheral blood
mononuclear cells (PBMCs) and TILs can quantitate the
effect of therapy on low-frequency immune subsets such
as Treg, MDSC, and activated CD8+ T cells [81]. The
biggest advantage of flow cytometry is the combination
of multiparameter measurements in a high-throughput
manner. With recent advances in laser and fluorochrome
technology, commercially available systems allow for de-
tection of up to 18 colors at analysis rates of more than
20,000 events per second. This tremendous power allows
for the analysis of multiple characteristics of rare cells
such as tumor antigen-specific T-lymphocytes, including
their phenotype and functional activity [82]. Flow cyto-
metric assays are currently widely used for the enumer-
ation and phenotypic characterization of lymphocytes,
measuring cytokines, secreted molecules, intracellular
signaling, function, and cell proliferation [83]. Using
polychromatic flow cytometry, multiple surface and intra-
cellular markers can be detected, allowing in-depth
characterization of T cell phenotype and activation state
[84]. In addition to flow cytometry, antigen-loaded soluble
major histocompatibility complex (MHC) tetramer stains
can be used to analyze tumor-specific T cell subpopula-
tions [82]. This tetramer/pentamer staining has been used
for phenotypic and quantitative analysis of antigen-
specific CD8 T cells [85, 86]. The human leukocyte anti-
gen (HLA) system is a gene complex encoding the MHC
Specimen Type of Assay Tumor-Derived Biomarker Immune Cell-Derived Biomarker
A  Tumor Protein (single 
or multiplex 
IHC)
PD-L1, PD-L2, TAAs CD8, CD4, CD3, CTLA-4, PD-1,
CD45RO, CD25, FOXP3, LAG-3, 
CD11b, CD57, CD68, co-stimulator(s)
Genomics WGS or WES for mutation 
load, neoantigens, MMR genes
T and/or B cell receptor deep 
sequencing
Transcriptomics Multigene signatures Multigene signatures, epigenomics
Function Proliferation marker: Ki67 Ki67, granzyme B





miRNA; serological biomarkers (soluble 
proteins, autoantibodies, cytokines or 
chemokines; HLA haplotyping
Cell based CTCs Immune cells 
C  Flow and 
mass cytometry
Phenotypic and functional characterization of different immune cells     
Activated T cells: CD3, CD4, CD8, Ki67, CTLA-4, PD-1, LAG-3, TIM-3, ICOS
Regulatory T cells: CD3, CD4, CD25, FOXP3, CD127, Ki67, CD45RA
Memory T cells: CD45RO
MDSC: CD14+HLA-DRlow
Detection and characterization of CTCs 
D  Antigen- 
specific T cell
monitoring
Characterization of tumor-antigen specific T cells:  
Sorting, Cloning, Binding avidity, Antigen-specific TCR and 
Functional assessment of response by tumor antigen-specific T cells:
HLA-class I and II tetramer, ELISPOT, Polyfunctional ICS, Natural tumor recognition
Fig. 2 Immune monitoring strategies for patients receiving checkpoint blockage therapy. Technologies that are currently used to assess the
potential immune biomarkers. a Tumor and immune cells in tumor specimens could be evaluated by immunohistochemical stain (IHC) or
immunofluorescence assays, molecular or genetic profiling analysis, and cellular functional assays. The tumor microenvironment can be
dissected histopathologically to characterize spatial relationships between tumor and immune infiltrates. Transcriptional profiling assays can
evaluate changes in gene expression in both the tumor cells and lymphocytes. Deep sequencing techniques enable quantification of changes
in individual T/B cell clonotypes. b Peripheral blood provides a minimally invasive way to allow serial monitoring of dynamic changes of
immune biomarkers during cancer immunotherapy. The analysis of changes in cell counts with therapy, changes in cytokine levels, circulating
tumor cells, tumor-derived nucleotides, and immune cells. c Flow cytometric analysis of TILs anPBMCs for quantitating the effect of therapy on
immune subsets such as activated CD8 + PD1+ T cells, CD4 + FOXP3 + CD25hi Tregs, or myeloid-derived suppressor cells. Using polychromatic flow
cytometry, multiple surface and intracellular markers can be detected, allowing in-depth characterization of T cell phenotype and activation state.
d Multifunctional flow T cell assay, MHC tetramer staining and ELISPOT can be used to analyze the presence and function of tumor-specific T
cell subpopulations. Abbreviations: PD-L1 programed death-1, IHC immunohistochemistry, ELISPOT enzyme-linked immunospot assay, CTCs
circulating tumor cells, WES whole exome sequencing, NGS next-generation sequencing, TIM-3 T cell immunoglobulin domain and mucin
domain, LAG lymphocyte-activation gene, ICOS inducible costimulators, MDSC myeloid-derived suppressor cells, HLA human leukocyte antigen
Ma et al. Journal of Hematology & Oncology  (2016) 9:47 Page 12 of 21
Table 3 Currently available translational biomarker assays for immune checkpoint inhibitors
Biospecimen Method Tissue/cell types Pros Cons References and
recommended reading
FFPE IHC Tumor cells or tumor
infiltrating immune
cells
Direct detection; accurately pinpoint cancer cells;
highly sensitive; simplicity; low cost
Requirement of trained pathologists; inconsistency
for criteria used to score tumors such as
PD-L1-positive or negative
Herbst R (2014) [145];
Loughlin PA (2007) [164]
Multicolor IHC Tumor cells or tumor
infiltrating immune
cells
Broad dynamic range; capability for multiplexing
using different fluorescence channels; >10
protein targets are identified in the same sample;
amenability for co-localization studies
Absence of rigorous quantitative tests; limitation
in some biomarker-driven clinical trials; user must





TILs T cell count information;
T cell clonality in tumor
Heterogeneous expression of TIL Robbins HS (2013) [100]
Whole exome
sequencing (WES)
Tumor cells Characterization of tumor mutation load including
nucleotide substitutions; structural rearrangements
and copy number alterations; identification of the
neoantigens and neoepitopes; affordable cost
Require high-performance deep sequencing,
computational bioinformatics support;
The pipelines are still at early developmental phase
Snyder A (2014) [104];
Rizvi NA (2015) [105];
Bouffet E (2016) [107];
Chen K-H (2016) [166]
Hugo W (2016) [106]
Blood ELISPOT assays
(IFNγ and granzyme B)
T cells in PBMCs Detection of tumor antigen-specific CD4+ and
CD8+ T cell response with good assay sensitivity;
Relatively well validated assay




Janetzki S (2008) [95]
Malyguine A (2012) [94];
Janetzki S (2015) [93];
Flow cytometry (tetramer,
polyfunctional analysis)
T cells in PBMCs Assessment of tumor antigen-specific CD4+ and
CD8+ T cells response; measure multiple functions;
detection of neoantigen-specific CD8 + PD-1+ T
cells; minimally invasive
Merely in lab research, not as routine clinical
monitoring yet
Yuan J (2008) [84];
Attic S (2011) [85];
McNeil LK (2013) [86];
Barrera L (2015) [168];





Analyses of the frequency and proliferation of
different subsets of immune cells; routine operation
Dedicated resource and staff to perform
the analyses
Streitz M (2013) [169];
van Dongen JJ (2012)
[170]
RNA-Seq (NGS) T cells in PBMCs Identification of genetic variants; a broader dynamic
range; detection of more differentially expressed
genes; fast and high efficiency
More expensive than microarray; more complex
for analysis; bulk signature, not single cell signals;
need more validation
Zhao S (2010) [171]
qPCR assay T cells in PBMCs High specificity; able to detect the reactivity of
low-frequency T cells in the peripheral blood of
metastatic cancer patients
Bulk signature, not single cell signals; need more
validation
Kammula US (2008) [172]
Flow cytometry CTCs Qualitative analysis at the single cell level in a
relatively short period of time; decrease the amount
of blood needed; provide valuable information
regarding the frequency, phenotype and/or the
functionality of T cells




CTCs PD-L1 levels from CTCs or CAMLs serves as a
surrogate for PD-L1 expression in tumor; as a
marker for immunotherapy response
Limited in lab research; need more validation Steven HL (2015) [173];
Adams DL (2014) [174]
Abbreviations: FFPE formalin-fixed paraffin-embedded, PD-L1 program death-1, TIL tumor-infiltrating lymphocytes, IHC immunohistochemistry, CAMLs cancer-associated macrophage-like cells, ELISPOT enzyme-linked
















Table 4 Immunohistochemistry assays for PD-L1 expression








ORR % in IHC+







Nivolumab 28-8 rabbit (Dako) 1 L Melanoma TCs Archival FFPE or
new biopsy
5 58 (46,69) 41 (35,48) Yes 0.001 Larkin J (2015) [130]
Nivolumab + ipilimumab 72 (60,82) 55 (48,62) Yes 0.001
Nivolumab ≥2 L 5 44 (30,58) 20 (11,32) Yes NA Weber JS (2015) [128]
Nivolumab + ipilimumab 1 L 5 58 (37,78) 55 (42,69) No >0.05 Postow MA (2015) [4]
Nivolumab 1 L 5 53 (41,64) 33 (25,42) No >0.05 Robert C (2015) [129]
≥2 L NSCLC TCs Archival FFPE or
new biopsy
1 31 (23,40) 9 (5,16) Yes 0.002 Paz-Ares L (2015) [156];
Updated in Borghaei H
(2015) [126]5 36 (26,46) 10 (6,17) Yes 0.002
10 37 (27,48) 11 (6,17) Yes 0.002
≥2 L Archival FFPE 1 17 (9,29) 17 (8,29) No 0.9364 Brahmer JR (2015) [125]
5 21 (10,37) 15 (8,25) No 0.2908
10 19 (8,36) 16 (9,26) No 0.6411
≥2 L Archival FFPE 1 20 (5,35) 13 (2,28) No >0.05 Rizvi NA (2015) [131]
5 24 (5,43) 14 (3,25) No
1 L Archival FFPE 5 31 (NA) 10 (NA) No >0.05 Gettinger SN (2015) [157]
Nivolumab + ipilimumab 1 L Archival FFPE 5 19 (NA) 14 (NA) No >0.05 Antonia SJ (2014) [158]
Nivolumab 5H1 and anti-PD-1
monoclonal M3
≥2 L Archival FFPE 5 39 (34,44) 6 (1,12) Yes 0.025 Taube JM (2014) [113]
Pembrolizumab 22C3 mouse (Dako) ≥1 L NSCLC TCs and
ICs
New biopsy 50 45 (33,57) 17 (10,25) Yes 0.001 Garon EB (2015) [5]
1 L New biopsy 50 47 (23,72) 19 (8,38) Yes NA Rival NA (2015) [159]
Any Archival FFPE 1 25 (NA) 13 (NA) Yes NA Garon EB (2014) [160]
≥1 L Archival FFPE 50 30 (23,39) 9.8 (NA) Yes NA Herbst RS (2015) [140]
29 (22,37) 10.7 (NA)









50 45 (23,68) 14 (6,25) Yes NA Leora H (2015) [162]
≥2 L NSCLC 1+ 31 (25,37) 20 (14,26) Yes 0.015 Herbst RS (2014) [145]
Solid
Tumor
1+ 29 (27,31) 13 (10,16) Yes 0.007





≥2 L NSCLC TCs Archival FFPE and
new biopsy
25 39 (NA) 5 (NA) Yes NA Segal NH (2014) [163]
33 (13,59) 30 (16,47) No for
combo
NA Antonia SJ (2016) [155];



















proteins in humans. HLA-peptide complexes binding to T
cell receptors could further define the specificity for epi-
topes and alleles [87]. Recently, mass cytometry or CyTOF
which replace the fluorescent labels with heavy metal ions
is under investigation for its application in immune bio-
marker research [88].
ELISA and protein microarray
Biomarkers in the blood have been pursued because speci-
mens are easy to collect and assays are available for serial
monitoring and quantitative measurements [89]. Enzyme-
linked immunoabsorbent assay (ELISA) is widely used to
assess the production of soluble mediators such as cyto-
kines, chemokines, and tumor antigen-specific antibodies
in peripheral blood before and after treatment. Novel pro-
tein microarray technologies such as ProtoArray® are
available to analyze the serological response of up to 9000
proteins simultaneously [90–92].
ELISPOT
Enzyme-linked immunospot (ELISPOT) assays are ro-
bust and standardized tests that quantify both the fre-
quency and function of T or B cells at the single cell
level. Both PBMCs and isolated CD4+ and CD8+ T cell
subsets could be stimulated by antigens and cultured in
a 96-well plate with a nitrocellulose membrane coated
with antibodies for cytokines of interest. These assays,
such as the IFNγ ELISPOT, have gained increasing
popularity for monitoring clinical trials and in basic re-
search [93–95]. Results from various clinical trials, in-
cluding peptide and whole tumor cell vaccination and
cytokine treatment, showed the suitability of the IFNγ
ELISPOT assay for monitoring T cell response [96].
ELISPOT assays revealed that 75 % of melanoma pa-
tients vaccinated with antigenic peptide demonstrated
specific immune responses [97, 98]. Besides IFNγ, other
cytokines such as IL-2, IL-5, IL-10, IL-17, granzyme B,
TNF, and granulocyte-macrophage colony-stimulating
factor (GM-CSF) are commonly measured by ELISPOT
assays. It has been expanded to more than 2~3 parame-
ters with the introduction of fluorescent dyes [99].
T cell or B cell receptor deep sequencing
To develop a robust, quantitative method with high re-
producibility, Robins et al. [100] uses a digital droplet
PCR technique call a QuanTILfy assay. High-throughput
quantitative sequencing of the rearranged TCR β genes
uses the ImmunoSeq assay. The TCR loci undergo som-
atic gene rearrangements in the 52 variable (V), diversity
(D), and 13 joining (J) regions of the β chain and vari-
able (V) and joining (J) regions of α chain. There are 52
Vβ segments and 13 Jβ segments that can rearrange.
With the right TaqMan probes-DNA from T cells can be
easily identified with reference to total DNA, as was
shown when purified human T cells were obtained from
a healthy donor and then diluted and mixed with human
lung fibroblasts at different ratios. This technique can
also identify clonal expansion (the mark of the adaptive
immune response). TCR deep sequencing has been used
to show the correlation between TCR repertoire and
clinical response to cancer immunotherapy in patients
with melanoma or prostate cancer treated with ipilimu-
mab [101]. Creation of a responder library for TCR
repertoire will greatly advance the field, especially for
genetically modified TCR cell transfer therapy.
WES for mutation load
The cancers that respond best to PD-1 inhibitors, such as
advanced melanoma and NSCLC, are the tumor types that
are genetically very complex with a high nonsynchronous
mutation load. This discovery led to an interest in neoan-
tigens (i.e., tumor-specific mutant antigens (TSMAs)) that
are immunogenic [102]. The advances in both affordable
next-generation sequencing (NGS) technology and bio-
informatics make it feasible to assess the full mutation
load in individual tumors and to identify neoantigens by
comparing WGS of tumor and normal tissues [103]. Com-
putation prediction algorithms and the tandem mini-gene
library allow for the evaluation of the immunogenicity of
both CD4+ and CD8+ T cell neoepitopes. Mutation load
and neoepitopes have been explored for their correl-
ation with clinical outcomes in cancer patients treated
with the PD-1/PD-L1 immune checkpoint blockade
[104–107]. However, whole exome sequencing (WES)
currently is not used in routine clinical practice. The
role of tumor load assessed in targeted exome sequencing
(TES) assays in predicting response to immune check-
point inhibitors remains to be determined.
Genetic susceptibility
Genetic factors are known to modulate the immune
response to a therapeutic protein product. In particu-
lar, some HLA haplotypes may predispose patients to
developing either exceptional or undesirable antibody
responses to immune checkpoint blockage therapies
[108]. If both are appropriate and feasible, HLA map-
ping studies may help define a subset of patients who
are at increased risk. Moreover, genetic polymor-
phisms in cytokine genes may upregulate or downreg-
ulate immune responses [109], which is why the FDA
recommends that researchers evaluate the genetic fac-
tors that may modulate the immune response to a
therapeutic protein. For example, the subset of pa-
tients who generate neutralizing antibodies to IFNβ
products are more likely to possess distinct HLA hap-
lotypes [108]. Thus, knowledge of the heightened
susceptibility of patients with such HLA haplotypes
may guide us to prevent such responses or pursuit
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Upregulation of PD-L1 expression level has been reported
in many different cancer types (e.g., melanoma (40–100 %),
NSCLC (35–95 %), and multiple myeloma (93 %)). High
levels of PD-L1 expression have been linked to poor clinical
outcomes [42, 110, 111]. Until now, anti-PD-L1 IHC on
tumor specimens is the most commonly used biomarker for
selecting patients who are likely to respond to treatments
[89]. Constitutively overexpressed PD-L1 in melanoma is
associated with poor clinical outcome [112]. However, the
PD-L1 overexpression in the context of CD8-positive cells
is associated with a better prognosis [113]. Although PD-L1
IHC using the 22C3 antibody has been approved by the US
FDA as the only predictive companion diagnostic for select-
ing NSCLC patients for pembrolizumab, tumor responses
have been seen in low PD-L1-expressing tumors. Conflict-
ing results have been reported with other PD-L1 antibodies
and drugs. Table 4 summarizes the reported data of PD-L1
IHC in current clinical trials.
Several tumor characteristics, such as a high mutation
load, smoking-related tumors, and tumors with mis-
match repair genes are associated with improved object-
ive tumor response rate (ORR), durable clinical benefit
(DCB), and PFS to immune checkpoint blockade anti-
bodies. Notably, whole exome sequencing has revealed
that a nonsynonymous mutation load of >200 per tumor
correlates with clinical responses to PD-1 mAb in
NSCLC, melanoma, and colorectal cancer with micro-
satellite instability (MSI; i.e., mutations in DNA mis-
match repair genes) [114–116]. Rizvi and his colleagues
showed that mutation load correlates with improved
ORR (63 versus 0 %), DCB (73 versus 13 %), and PFS
(14.5 versus 3.7 months) [105]. Moreover, the efficacy
was associated with a molecular smoking signature. The
ORR was 56 and 17 % in transversion-high tumors and
transversion-low tumors, respectively; the rate of DCB
was 77 versus 22 %, respectively; and the PFS was also
significantly longer in transversion-high tumors com-
pared to transversion-low tumors. Efficacy was also con-
nected with higher neoantigen burden, but additional
genetic features are likely to play a role in determining
the tumor response [116, 117]. Neoantigen-specific CD8+
T cell responses paralleled tumor regression in one re-
sponder, implying that anti-PD-1 therapy enhanced
neoantigen-specific T cell reactivity [118].
Immune cell-derived biomarkers
TIL cells have been shown to express significantly higher
levels of PD-1 than T cells in normal tissue [119]. The
tumor microenvironment may secrete pro-inflammatory
cytokines to upregulate the expression of PD-1 on TIL
cells to ensure that they can respond to the high
levels of PD-L1 expressed on the tumor [120]. Preexisting
CD8+ T cells distinctly located at the invasive tumor mar-
gin are associated with expression of the PD-1/PD-L1
immune inhibitory axis [121]. The proliferation of intratu-
moral CD8+ T cells directly correlated with radiographic
reduction in tumor size in metastatic melanoma patients
treated with pembrolizumab. Pretreatment samples ob-
tained from responding patients showed higher numbers
of CD8+ T cells, PD-1, and PD-L1-expressing cells at the
invasive tumor margin and inside tumors, with a more
clonal TCR repertoire. Using multivariate analysis, re-
searchers established a predictive model based on CD8 ex-
pression at the invasive margin and validated the model in
an independent cohort of 15 patients. Their findings indi-
cate that tumor regression after PD-1 blockade requires
preexisting CD8+ T cells that are negatively regulated by
PD-1/PD-L1-mediated adaptive immune resistance. In
addition, the tumor microenvironment can be dissected
histopathologically in order to characterize spatial rela-
tionships between tumor and immune infiltrate, and tran-
scriptional profiling assays can evaluate changes in gene
expression in both the tumor and in lymphocytes [122].
Given that TIL in the tumor microenvironment affects
the prognosis of the tumor, a new TNM Immune system
(TNM-I) system has been proposed and is currently be-
ing validated by an international consortium [123]. Early
studies suggest that activated T cells are not pharmaco-
dynamic markers of nivolumab treatment [124]. It re-
mains to be determined whether nivolumab treatment
increases CD8 effector memory cells in cancer patients.
With technical advances, detection of CD8-positive,
PD-1-positive T cells in the peripheral blood of melan-
oma patients receiving PD-1 inhibitors is feasible. Fur-
thermore, the tumor-antigen specificities and TCR
repertoires of the circulating and tumor-infiltrating
CD8+PD-1+ cells appeared similar [118].
Conclusions
The era of cancer immunotherapy has arrived. This
major breakthrough in cancer treatment holds great
promise for increasing cure rates for patients with vari-
ous cancer types in multiple disease settings. Checkpoint
blockade antibodies targeting CTLA-4, PD-1, and PD-L1
axis have demonstrated impressive and durable disease
control and promising responses in patients with mul-
tiple tumor types. Despite these advances, only a subset
of patients benefits from immune checkpoint blockade
therapies, with some patients experiencing mechanism-
based irAEs. Translational biomarker research is one
way to overcome these limitations of therapy. Bio-
markers play a critical role in understanding potential
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mechanisms of action in patients, identifying patients
who are likely to respond to the growing list of cancer
therapeutics and avoiding the irAEs. Several tumor-de-
rived biomarkers have been reported from recent cor-
relative studies including PD-L1 expression on tumor
cells, high tumor mutational load, and neoantigens. In
addition, several immune cell-derived biomarkers showed
better correlation with the clinical outcomes. The pres-
ence of TILs in tumor microenvironments, increased PD-
L1 expression on immune cells, and the ratio of effector
CD8+ T cells to FoxP3+ regulatory T cells in tumors are
some examples of markers for clinical outcomes. Future
studies are warranted to harmonize companion diag-
nostics (such as PD-L1 IHC) for accurate clinical as-
sessment and application of the class of PD-1/PD-L1
inhibitors. It is of importance to further evaluate muta-
tion load as a potential biomarker and develop effect-
ive tumor antigen-specific T cell assays to differentiate
immunogenic neoepitopes from putative ones. The ad-
vances in translational immune biomarker research are
essential for personalized cancer immunotherapy as ei-
ther monotherapy or combinational therapy.
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